Understanding The Business Model Of Gene Therapy Companies – Peeling The Onion Back To Understand Why Time Matters

by Biotech Newsroom


By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC

Moving from traditional drug development and commercialization to gene therapy development and commercialization can be compared to moving from horses to cars as modes of transportation. That’s the analogy our CSO, Chris Mason, uses to describe the difference. Horses and cars were both game changers for transport in their respective eras (and cars continue to be), but both required different strategies to thrive.

Instead of building barns and growing hay and oats for horses,…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC